The NM_000203.5:c.956C>T variant in IDUA is a missense variant predicted to cause substitution of alanine by valine at amino acid 319 (p.Ala319Val). One patient from Pakistan, homozygous for the variant, was diagnosed with attenuated MPS I (described as having Scheie syndrome) and low IDUA activity (PMID: 11735025) (PP4, PM3_supporting). The highest population minor allele frequency in gnomAD v4.1.0 is 0.0001673 (1/5976 alleles) in the Middle Eastern population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.00025), meeting this criterion (PM2_Supporting). When expressed in COS cells, the activity of the variant was indistinguishable from that of untransfected COS cells (PMID: 11735025) (PS3_Supporting). The computational predictor REVEL gives a score of 0.896 which is above the threshold of 0.773, evidence that correlates with impact to IDUA function at the moderate level based on the specifications of the ClinGen Lysosomal Diseases VCEP (PMID: 36413997) (PP3_Moderate). There is a ClinVar entry for this variant (Variation ID: 1683230). In summary, this variant meets the criteria to be classified as likely pathogenic for mucopolysaccharidosis type I based on the IDUA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Expert Panel (Specifications Version 1.0.0): PP3_Moderate, PP4, PS3_Supporting, PM2_Supporting, PM3_Supporting. (Classification approved by the ClinGen Lysosomal Diseases Expert Panel, August 8, 2025)